AC Immune S.A.

5 trials 5 recruiting Commercial sponsor Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

4 Countries active

5 Unique IMPs

N/A Results reported

Phase II

Phase I/II

Phase I

Phase II: 1 Phase I/II: 1 Phase I: 3

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Top indications

Parkinson's disease 2 Amyotrophic lateral sclerosis 1 Multiple system atrophy 1 Frontotemporal dementia 1 Dementia with Lewy bodies 1

Top IMPs

FLORBETABEN (18F) 1 IOFLUPANE (123I) 1 IZAFLORTAUCIPIR (18F) 1 PAL1-15 ACETATE 1 PD01B 1

All trials

5 total

A Single-Center, Double-Blind, Randomized, Placebo Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and P… Recruiting

2025-523885-25-00 Phase I 1 country
Phase 1 study to evaluate [18F]ACI-15916 as a potential PET radioligand for imaging α-synuclein deposits in the brain of patients with suspe… Recruiting

2024-515664-31-00 Phase I 1 country
Phase 1 study to evaluate [18F]ACI-19626 as a potential PET radioligand for imaging TDP-43 inclusions in the brain of patients with suspecte… Recruiting

2024-513097-21-00 Phase I 1 country
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, … Recruiting

2022-500292-31-00 Phase II 2 countries IOFLUPANE (123I); PD01B
A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, … Recruiting

2022-500069-29-00 Phase I/II 1 country FLORBETABEN (18F); IZAFLORTAUCIPIR (18F); PAL1-15 ACETATE

Showing 1–5 of 5 trials

← All sponsors A–Z